Granules India Limited — Investor Meet, 29-04-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Granules India reported a landmark FY26: revenue up 20% YoY to ₹5,365.6 Cr, EBITDA up 25% to ₹1,185.1 Cr (22.1% margin), and PAT up 19% to ₹595 Cr. Q4FY26 saw robust revenue of ₹1,470.6 Cr (+23% YoY) with EBITDA at ₹352.1 Cr (23.9% margin). The company achieved record gross margins and significantly deleveraged to 0.34x Net Debt/EBITDA. Management emphasized a strategic shift towards Complex Generics, now 43% of formulations, and the new Peptide CDMO platform. Growth is diversified across regions, supported by substantial CAPEX and R&D in high-barrier segments. The outlook suggests continued focus on higher-value products and operational efficiency.